NCT00853840

Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

A Randomized, Single-Blinded, Placebo-Controlled Two-Way Crossover Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The objective of this study was to estimate the effects of a single dose of vardenafil on the blood pressure (BP) in subjects receiving maraviroc (MVC) (dosed to steady-state) and to assess the safety and tolerability of MVC in subjects receiving a single dose of vardenafil.

Conditions

• AIDS

Interventions

Type	Name	Description
DRUG	Maraviroc	Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
DRUG	Vardenafil	Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
DRUG	Maraviroc	Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
DRUG	Placebo	Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.

Timeline

• Start date: 2008-04-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2009-03-02
• Last updated: 2013-01-25
• Results posted: 2009-06-23

Locations

1 site across 1 country: Belgium